(@james.ferrara)

Goal 2: Reduce Human Disease

Personalized therapy of HCT complications

Can biomarkers make all the use of new predictive biomarkers enable earlier and more effective treatment of acute GVHD? Can biomarkers accurately guide reduction in therapy for patients who will respond to standard steroid treatment? Can biomarkers enable earlier and thus more effective therapy for high risk GVHD? Can new biomarkers (proteomic, genomic or a combination) also predict patients who are risk of relapse?

Voting

74 net votes
99 up votes
25 down votes
Active
(@giralts)

Goal 2: Reduce Human Disease

What are the mechanisms of lung injury after HCT

Despite major advances in supportive care and tissue typing non relapse mortality rates for adults undergoing hematopoietic cell transplantation are still between 15-20 % at 2 years. Lung injury and respiratory failure is a major causes of death after HCT. Although the BMT-CTN has a focused agenda on GVHD, reduction of lung toxicities will be important to improve outcomes. NHLBI should encourage researched from the... more »

Voting

59 net votes
88 up votes
29 down votes
Active
(@k.willard)

Goal 3: Advance Translational Research

Predicting COPD exacerbations and relapse

What measures other than PFT data can be used to predict risk of 1) COPD exacerbations (e.g., hospitalization, urgent care visit, or ED visit for COPD exacerbation) or 2) relapse (e.g., re-hospitalization, urgent care visit, or ED visit) following hospital discharge after treatment of COPD exacerbations?

Voting

14 net votes
16 up votes
2 down votes
Active